Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs iShares MSCI Japan ETF (EWJ) Price & Performance

Amgen, Inc.Trade
iShares MSCI Japan ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs iShares MSCI Japan ETF — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while iShares MSCI Japan ETF trades at $97.37. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals.

AMGNEWJ
Market Cap
$224.14B
Sector
HealthBroad Market / Factor
52-Week High
$417.20$96.97
52-Week Low
$271.18$77.93
Enterprise Value
$267.45B
Dividend Yield
2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ